CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
perioperative chemotherapy plus bevacizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02399410
NCT02399410Phase 2Completed
CompareCT.gov

BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis

University Hospital, Ghent·interventional·Posted Mar 26, 2015·Updated Jan 30, 2024

In Brief

A Phase 2 clinical trial evaluating perioperative chemotherapy plus bevacizumab, cytoreductive surgery, and 1 other intervention for Colorectal Neoplasms. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The Bev-IP trial is designed to assess the feasibility and efficacy of a combined treatment consisting of perioperative combination chemotherapy with the vascular endothelial growth factor A inhibitor bevacizumab and cytoreductive surgery with intraperitoneal oxaliplatin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms
CountriesBelgium
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 26, 2015
Enrollment StartNov 4, 2015
Primary CompletionNov 9, 2023
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 11.3 years ago

Interventions

perioperative chemotherapy plus bevacizumabdrug

preoperative and postoperative combination chemotherapy with bevacizumab

cytoreductive surgeryprocedure

complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.

Intraperitoneal Oxaliplatindrug

Pump-driven intraperitoneal administration of oxaliplatin